Dr.
Carlos Gil Moreira Ferreira
Oncologista
·
Mais
sobre as especializações
Rio de Janeiro 1 endereço
Número de registro: CRM: 198195-SP RQE Nº: 76246 CRM: 571988-RJ RQE Nº: 32902
2 opiniõesExperiência
Formado pela Universidade Federal de Juiz de Fora, com especialização em Clínica Médica e Oncologia Clínica (1997). Trabalhou por 4 anos na Vrije Universiteit de Amsterdam entre 1997 e 2001, onde realizou PhD em genômica aplicada ao desenvolvimento de novas terapias antineoplásicas, fellowship em pesquisa clínica e fellowship em oncologia torácica (foco em câncer de pulmão). Atuou como Pesquisador Sênior e Chefe da Divisão de Pesquisa Clínica do Instituto Nacional de Câncer entre 2002 e 2015. Idealizador e Coordenador de projetos estratégicos como o Banco Nacional de Tumores (BNT-INCA), Rede Nacional de Pesquisa Clínica em Câncer (RNPCC) e Rede Nacional para o Desenvovimento de Drogas Anticâncer (REDEFAC) do DECIT/MS. Editor de 3 livros em Oncologia (Prêmio Jabuti em 2005) e autor de mais de 150 artigos em revistas internacionais e capítulos de livro.
Recebedor de vários prêmios internacionais, dentre eles o Partner in Progress da ASCO em 2020 e os Prêmios de Melhor Equipe para o tratamento de pacientes com câncer de pulmão da América Latina, concedido pela International Association for the Study of Lung Cancer (IASLC) em 2017 e 2019.
A base para esse último prêmio é o modelo inovador de atendimento integrado e multidisciplinar. Todos os pacientes são acompanhados simultaneamente por oncologistas clínicos, radiooncologistas, especialistas em genômica, oncogeneticistas, enfermeiras navegadoras, nutricionistas, farmacêuticos clínicos e . fisioterapeutas. Como resultado uma melhoria dos resulatdos e da qualidade de vida dos pacientes.
mais
Sobre mim
Recebedor de vários prêmios internacionais, dentre eles o Partner in Progress da ASCO em 2020 e os Prêmios de Melhor Equipe para o tratamento de pacientes com câncer de pulmão da América Latina, concedido pela International Association for the Study of Lung Cancer (IASLC) em 2017 e 2019.
A base para esse último prêmio é o modelo inovador de atendimento integrado e multidisciplinar. Todos os pacientes são acompanhados simultaneamente por oncologistas clínicos, radiooncologistas, especialistas em genômica, oncogeneticistas, enfermeiras navegadoras, nutricionistas, farmacêuticos clínicos e . fisioterapeutas. Como resultado uma melhoria dos resulatdos e da qualidade de vida dos pacientes.
Experiência em:
- Oncologia clinica
- Oncologia torácica
Principais doenças tratadas
- Câncer de mama
- Câncer de estômago
- Câncer colorretal
- Câncer de pâncreas
- Câncer de próstata
- +3 a11y_sr_more_diseases
Pacientes que trato
Adultos
Experiência
Carlos Gil Moreira Ferreira
Oncologista
Formação
- Universidade Federal de Juiz de Fora (UFJF) - Graduação em Medicina 1992
- Universidade Estadual do Rio de Janeiro (UERJ) - Residência em Clínica Médica (1993)
- Instituto Nacional de Câncer (INCA) - Residência em Oncologia Clínica (1997)
- Vrije Universiteit Amsterdam - PhD em Desenvolvimento de Novas Drogas Anticâncer (2001)
- Vrije Universiteit Amsterdam - Fellowship Pesquisa Clínica (2001)
- Vrije Universiteit Amsterdam - Fellowship Oncologia Torácica (2001)
Doenças tratadas
- Câncer de mama
- Câncer de estômago
- Câncer colorretal
- Câncer de pâncreas
- Câncer de próstata
- Câncer de pulmão
- Câncer de esôfago
- Câncer de rim
Publicações
- COVID-19 in patients with lung cancer (Annals of Oncology, 2021)
- Independent real-world application of a clinical-grade automated prostate cancer detection system (Journal of Pathology, 2021)
- Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in Brazil (JCO Global Oncology, 2021)
- Lung Stereotatic Body Radiation Therapy: Outcomes from a Brazilian Cohort (Journal of Thoracic Oncology, 2021)
- Access of Patients With Lung Cancer to High Practice in Brazil Technology Radiation Therapy in Brazil (JCO Global Oncology, 2021)
- A comparison Between the Cost of Lung Cancer Treatment and how much is made Available by Brazilian Government (Journal of Thoracic Oncology, 2021)
- Cyclic ACTH-secreting thymic carcinoid: a case report and review of the literature (Archives of Endocrinology and Metabolism, 2021)
- Barries in Precision Medicine Implementation Among Advanced Nonsquamous Cell Lung Cancer-Patients: A Real-World Scenario (Journal of Thoracic Oncology, 2021)
- The Clinical Pharmacist as a Member of a Multidisciplinary Team for Lung Cancer Patients Assistance (Journal of Thoracic Oncology, 2021)
- Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients (BMC Cancer, 2021)
- Individualized Nutritional Management in Patients Eligible for Thoracic Surgery Experience of a Chest Tumor Center in Brazil (Journal of Thoracic Oncology, 2021)
- Dealing with lung cancer in the COVID‑19 scenario (A review - Molecular and clinical oncology, 2021)
- Tumor-Node-Metastasis Stagin and treatment patterns of 73.167 patients with lung cancer in Brazil (BRAS PNEUMOL. 2020)
- Next-generation sequencing of circulating tumor dna for metastatic non-small cell lung cancer: a discussion on its implementation in the brazilian clinical practice (Future Oncology, 2020)
- Brazilian women with lung cancer have a higher overall survival that their mal equivalents: a cohort study (Clin Lung Cancer, 2020)
- IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens following neoadjuvant therapy (Thorac. Oncology, 2020)
- Protective action of melatonin on diabetic rat testis at cellular, hormonal and immunohistochemical levels (EPUB, 2020)
- Effect of melatonin on gonad and thyroid development of offspring of hypothyroid pregnant rats (EPUB, 2020)
- Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion gene (Journal of Cancer 2020
- Prembolizumab versus Chemotherapy for previously untreated, pd – l1 expressing, locally advanced or metastatic non-small-cell lung cancer (keynote – 042): a randomised, open label, controlled, phase-3 trial (The Lancet, 2020)
- Cancer Immunotherapy: the art of targeting the tumor immune microenvironment (EPUB, 2019)
- Increasing access to next-generation sequencing in Oncology for Brazil (Lancet, 2019)
- The value of biomarkers in optimizing the use of immuno-oncologic therapy (Current Drug Targets, 2019)
- Morphological and immunohistochemical study of the midgut and fat body of Spodoptera frugiperda (J.E. Smith) (Lepidoptera: noctuidae) treated with essential oils of the genus Piper (EPUB, 2019)
- Development and evaluation of a mobile decision support system for hypertension management in the primary care setting in brazil: mixed-methods field study on usability, feasibility, and utility (2019)
- Lung cancer in Brazil (Jornal Brasileiro de Pneumologia, 2018)
- Increased incidence, morbidity and mortality rates for lung cancer in women in Brazil between 2000 and 2014: An analysis of three types of sources of secondary data (Lung Cancer, 2018)
- Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer ( Brazilian Journal of Medical and Biological Research, 2018)
- cDNA microarray analysis of human keratinocytes cells of patients submitted to chemoradiotherapy and oral photobiomodulation therapy: pilot study (Lasers in Medical Science, 2018)
- The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries (BMC Medical Education, 2018)
- Human CHD1 is required for early dna-damage signaling and is uniquely regulated by its n terminus (NUCLEIC ACIDS RES, 2018)
- A cross-sectional study examining the expression of splice variants k-ras4a and k-ras4b in advanced non-small-cell lung cancer patients (EPUB, 2018)
- Radiotherapy modulates expression of egfr, ercc1 and p53 in cervical cancer (BRAS J MED BIOL RES, 2018)
- Response to "commentary on: undertreatment trend in elderly lung cancer patients in Brazil" (EPUB, 2017)
- CDNA microarray analysis of human keratinocytes cells of patients submitted to chemoradiotherapy and oral photobiomodulation therapy: pilot study (EPUB, 2017)
- SNORNA and PIRNA expression levels modified by tobacco use in women with lung adenocarcinoma (JOURNAL.PONE,2017)
- Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer (GYNECOL ONCOL, 2017)
- Long-term survival of a randomized phase iii trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (lllt) to prevent oral mucositis (ORAL ONCOL, 2017)
- XAF 1 Expression levels in a non-small cell lung cancer cohort and its potential association with carcinogenesis (ONCOL REP, 2017)
- Functional analysis of polymorphisms in the cox-2 gene and risk of lung cancer (MOL CLIN ONCOL, 2017)
- Undertreatment trend in elderly lung cancer patients in Brazil (CANCER RES CLIN ONCOL, 2017)
- Maternal NA+ INTAKE induces renal function injury in rats prevented by a short-term angiotensin converting enzyme inhibitor (CLIN EXP Pharmacol Physiol, 2017 )
- Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing (LANCET ONCOL, 2016)
- Potential impact of MTOR inhibitors on cervical squamous cell carcinoma: a systematic review (ONCOL LETT, 2016)
- Brazilian health-care policy for targeted oncology therapies and companion diagnostic testing (LANCET ONCOL, 2016)
- Cholangiocarcinoma associated with limbic encephalitis and early cerebral abnormalities detected by 2-deoxy-2-[fluorine-18]fluoro-d-glucose integrated with computed tomography-positron emission tomography: a case report (J MED CASE REP. 2016)
- Epidemiological profile and quality indicators in patients with acute coronary syndrome in northern Minas Gerais - Minas telecardio 2 project (BRAS CARDIOL, 2016)
- Epidemiological changes in the histological subtypes of 35,018 non-small-cell lung cancer cases in Brazil (J.LUNGCAN,2016)
- Unveiling alterative splice diversity from human oligodendrocyte proteome data (EPUB, 2016)
- A phase I study of MTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I (EPUB, 2016)
- IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of k-ras-mutant lung cancer (EPUB, 2016)
- Colorectal cancer: epidemiology, disease mechanisms and interventions to reduce onset and mortality (CLIN COLORECTAL CANCER, 2016)
- Neoadjuvant chemotherapy followed by chemoradiation in cervical carcinoma: a review (INT J GYNECOL CANCER, 2016)
- Cost-effectiveness of low-level laser therapy (lllt) in head and neck cancer patients receiving concurrent chemoradiation (ORAL ONCOL, 2016)
- Efficacy of a standardized computer-based training curriculum to teach echocardiographic identification of rheumatic heart disease to nonexpert users (J Cardiol, 2016)
- Different therapeutic outcomes of benznidazole and VNI treatments in different genders in mouse experimental models of trypanosoma cruzi infection (EPUB, 2015)
- Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. (EUR J SURG ONCOL, 2015)
- Combined analysis of SNP array data identifies novel CNV candidates and pathways in ependymoma and mesothelioma (BIOMED RES INT, 2015)
- Impact of pre-analytical variables on cancer targeted gene sequencing efficiency (PLoS One, 2015)
- Carboplatin plus pemetrexed offers superior cost-effectiveness compared to pemetrexed in patients with advanced non-small cell lung cancer and performance status (LUNG CANCER, 2015
- Use of (99M) TC-DOXORUBICIN scintigraphy in females with breast cancer: a pilot study (J. RADIOL, 2015)
- Mutational profile and new IASLC/ATS/ERS classification provide additional prognostic information about lung adenocarcinoma: a study of 125 patients from Brazil (VL. Oncology, 2015)
- The effect of tobacco additives on smoking initiation and maintenance (CAD SAUDE PUBLICA, 2015)
- The effect of sediment mimicking drill cuttings on deep water rhodoliths in a flow-through system: experimental work and modeling (J.MARPOLBUL.2015)
- First-line crizotinib versus chemotherapy in alk-positive lung cancer (N ENGL J MED, 2014)
- Splice variants in the proteome: a promising and challenging field to targeted drug discovery (J.DRUDIS,2014)
- Subarachnoid clonidine and trauma response in cardiac surgery with cardiopulmonary bypass (REV BRAS ANESTESIOL, 2014)
- Survival and prognostic factors in patients with non-small cell lung cancer treated in private health care (REV BRAS EPIDEMIOL, 2014)
- Human CHD2 is a chromatin assembly atpase regulated by its chromo- and dna-binding domains (J BIOL CHEM, 2014)
- Treatment of ovarian cancer beyond chemotherapy: are we hitting target? (CANCER CHEMOTHER PHARMACOL, 2015 )
- Prevalence of human papillomavirus infection and phylogenetic analysis of hpv-16 e6 variants among infected women from northern Brazil (INFECT AGENT CANCER, 2014)
- In-vitro antiviral efficacy of ribavirin and interferon-alpha against canine distemper virus (J VET RES, 2014)
- Comparison of adenocarcinoma (aca) and squamous cell carcinoma (scc) of the uterine cervix in a sub-optimally screened cohort: a population-based epidemiologic study of 51,842 women in Brazil (GYNECOL ONCOL, 2014)
- Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer (EPUB, 2014)
- A time-compressed simulated geomagnetic storm influences the nest-exiting flight angles of the stingless bee tetragonisca angustula (EPUB, 2014)
- Antiangiogenesis beyond vegf inhibition: a journey from antiangiogenic single-target to broad-spectrum agents (CANCER TREAT REV, 2014)
- Spliceprot: a protein sequence repository of predicted human splice variants (PROTEOMICS, 2014)
- Thoracoscopic treatment of congenital diaphragmatic eventration in children: lessons learned after 15 years of experience (EPUB, 2014)
- Reply to phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma (EPUB, 2013)
- Lower pole vessels in children with pelviureteric junction obstruction: laparoscopic vascular hitch or dismembered pyeloplasty (J PEDIATR UROL, 2013)
- Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and eastern cooperative oncology group performance status of 2 (J CLIN ONCOL, 2013)
- The adolescent and young adult with cancer: state of the art--epithelial cancer (CURR ONCOL REP, 2013)
- Lung cancer in developing countries: access to molecular testing (SOC CLIN ONCOL EDUC BOOK, 2013)
- First occurrence of amblyomma ovale in the state of Rio Grande do Norte, Brazil (J VET, 2013)
- Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma (EPUB, 2013)
- Simulation of the mutation f76del on the von hippel-lindau tumor suppressor protein: mechanism of the disease and implications for drug development (EPUB, 2012)
- Campanulotes compar (burmeister, 1838) (phthiraptera: ischnocera) in chickens (gallus gallus domesticus) from Rio Grande do Norte State, Brazil. The reemergence of an ectoparasite? (EPUB, 2013)
- National prevalence survey in Brazil to evaluate the quality of microbiology laboratories: the importance of defining priorities to allocate limited resources (REV PANAM SALUD PUBLICA,2013)
- Bioinformatics of cancer NCRNA in high throughput sequencing: present state and challenges (ECOLLECTION, 2012)
- Simulation of the mutation f76del on the von hippel-lindau tumor suppressor protein: mechanism of the disease and implications for drug development. (PROTEINS, 2012)
- Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing egfr mutation (J THORAC ONCOL, 2012)
- Involvement of signaling molecules in the prediction of response to imatinib treatment in metastatic gist patients (J SURG RES, 2012)
- Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy? (SUPPORT CARE CANCER. 2012)
- Identical sequence patterns in the ends of exons and introns of human protein-coding genes (COMPUT BIOL CHEM, 2012)
- Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation (RADIOTHER ONCOL. 2012)
- Gastrointestinal stromal tumor: analysis of 146 cases of the center of reference of the national cancer institute— INCA (REV COL BRAS CIR, 2012)
- Azetidinyl oxadiazoles as potent mglur5 positive allosteric modulators (BIOORG MED CHEM LETT. 2012)
- Efficient blockade of akt signaling is a determinant factor to overcome resistance to matuzumab (MOL CANCER, 2011)
- Pectus excavatum repair according to nuss: is it safe to place a retrosternal bar by a transpleural approach, under thoracoscopic vision? (ADV SURG TECH A, 2011)
- Segtor: rapid annotation of genomic coordinates and single nucleotide variations using segment trees (PLOS ONE, 2011)
- Amyloid-like fibrils are not detected in non-small cell lung cancer tissue samples (MED ONCOL, 2011)
- Modified spitz procedure using a collis gastroplasty for the repair of long-gap esophageal atresia (EUR J PEDIATR SURG, 2011)
- Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account? (J CLIN ONCOL, 2011)
Prêmios
- 2020- Partners in Progress da ASCO (American Society of Clinical Oncology)
- 2019 - IALSC Melhor Grupo de Oncologia Torácica da America Latina
- 2017 - IALSC Melhor Grupo de Oncologia Torácica da America Latina
Serviços e preços
-
Consulta Cancerologia
A partir de R$ 1.350 -
-
Primeira consulta cancerologia
A partir de R$ 1.350 -
-
Retorno de consultas cancerologia
A partir de R$ 1.350 -
-
Teleconsulta
A partir de R$ 1.350 -
-
Consulta oncologista
R$ 1.350 -
Consultórios (2)
Oncoclinicas Botafogo
Praia de Botafogo, 300, Botafogo, Rio de Janeiro 22251-060
Disponibilidade
Este especialista não oferece agendamento online neste endereço
Teleconsulta
Disponibilidade
Este especialista não oferece agendamento online neste endereço
Planos de saúde aceitos
Os planos de saúde são aceitos, mas a cobertura varia de acordo com o local e o serviço. Confirme durante a etapa de agendamento!
Opiniões
2 opiniões
Todas as opiniões são importantes, por isso os especialistas não podem pagar para alterar ou excluir uma opinião.
Saiba mais.
Saber mais sobre pareceres
-
B
Bruno Maia
Sou paciente do Dr. Carlos Gil desde 2018 e ele é excelente! Além de ser uma referência mundial em oncologia ele é super atencioso, sempre pronto a responder em qualquer emergência, super cuidadoso e explica tudo o que você perguntar detalhadamente e o mais importante de tudo é que ele te deixa tranquilo em relação aos tratamentos pois você percebe que ele sabe 100% o que está fazendo. Fiz 2 quimios, 2 radios e 1 imuno e hoje estou em controle do meu tumor que foi um caso extremamente raro.
• Oncoclinicas Botafogo • Consulta Cancerologia •
-
J
Juliana
O paciente e familiares não conseguem contato algum com o médico, ele manda a sua equipe que é totalmente perdida , ficar em contato com a família. [Editado Doctoralia].
Não recomendo.
Muito descaso !• Oncoclinicas Botafogo • Outro •
Perguntas frequentes
-
Quais são as principais especialidades de Carlos Gil Moreira Ferreira?Carlos Gil Moreira Ferreira é oncologista. Te mostramos alguns dos serviços oferecidos pelo especialista graças à sua trajetória e vasta experiência: Teleconsulta, Primeira consulta cancerologia, Retorno de consultas cancerologia, Consulta Cancerologia, Consulta oncologista.
-
Onde fica o consultório de Carlos Gil Moreira Ferreira?Carlos Gil Moreira Ferreira atende em:
- Praia de Botafogo, 300 Rio de Janeiro
-
Posso passar por atendimento online com Carlos Gil Moreira Ferreira, sem ter que ir até o consultório?Não, no momento Carlos Gil Moreira Ferreira não oferece atendimento online.
-
Quais métodos de pagamento são aceitos por Carlos Gil Moreira Ferreira?Carlos Gil Moreira Ferreira aceita os seguintes métodos de pagamento: Dinheiro, Transferência Bancária, PIX.
-
Em quais idiomas Carlos Gil Moreira Ferreira atende?Carlos Gil Moreira Ferreira atende em Inglês, Português, Espanhol, Holandês.
-
Como posso marcar uma consulta com Carlos Gil Moreira Ferreira?Carlos Gil Moreira Ferreira ainda não indicou os horários que tem disponíveis neste endereço. Recomendamos que entre em contato diretamente com o especialista para conhecer sua disponibilidade.
-
Quando poderia me consultar com Carlos Gil Moreira Ferreira?Entre em contato diretamente com Carlos Gil Moreira Ferreira para verificar sua disponibilidade.
-
O que outros pacientes opinam sobre Carlos Gil Moreira Ferreira?Um total de 2 pacientes já deixou uma opinião honesta e real sobre Carlos Gil Moreira Ferreira, que tem uma avaliação média de 3 estrelas (de 5).
-
Quais são os convênios aceitos por Carlos Gil Moreira Ferreira?Carlos Gil Moreira Ferreira não aceita convênios, apenas pacientes particulares. Recomendamos que caso tenha alguma dúvida, entre em contato com o especialista.
Oncologistas próximos
Doenças mais tratadas